Lymphoblastic Leukemia, Acute Clinical Trial
Official title:
Pilot Study of Genetically Modified Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia
This study will determine the maximum tolerated dose of genetically modified natural killer (NK) cells in research participants with relapsed or refractory B-lineage acute lymphoblastic leukemia (ALL).
NK cell cytotoxicity is most powerful against acute myeloid leukemia (AML) cells, whereas
their capacity to lyse ALL cells is generally low and difficult to predict. A novel method
has been developed to redirect NK cells towards CD19, a molecule highly expressed on the
surface of B-lineage ALL cells, but not expressed on normal cells other than B-lymphocytes.
In this method, donor NK cells are first expanded by co-culture with irradiated K562 cell
line modified to express membrane bound IL-15 and 41BB ligand (K562-mb15-41BBL).
Overexpansion of these proteins promotes selective growth of NK cells. Then, the expanded NK
cells are transduced with a signaling receptor that binds to CD19 (anti-CD19-BB-zeta). NK
cells expressing these receptors showed powerful anti-leukemic activity against CD19+ ALL
cells in vitro and in an animal model of leukemia.
This study represents the translation of laboratory findings into clinical application. It
will allow us to assess the safety of infusing genetically modified NK cells into research
participants who have chemotherapy refractory or relapse B-lineage ALL. In this same cohort,
we also intend to study the in vivo lifespan and phenotype of genetically modified NK cells
and explore the efficacy of NK cells in patients with B-lineage ALL.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00391989 -
Treatment of Adult Ph+ LAL With BMS-354825
|
Phase 2 | |
| Recruiting |
NCT00131027 -
High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL)
|
Phase 3 | |
| Recruiting |
NCT00131053 -
Applying Pediatric Regimens to Younger Adult Patients With Acute Lymphoblastic Leukemia (ALL)
|
Phase 2 | |
| Terminated |
NCT01100658 -
Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors
|
N/A | |
| Completed |
NCT00137111 -
Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
|
Phase 3 | |
| Recruiting |
NCT02879643 -
Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapsed ALL
|
Phase 1 | |
| Terminated |
NCT00798213 -
SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)
|
Phase 2 | |
| Recruiting |
NCT02888977 -
Tyrosine Kinase Inhibitors and Low Intensity Chemotherapy in Ph+ ALL
|
||
| Terminated |
NCT01186328 -
EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)
|
Phase 1 | |
| Completed |
NCT00114348 -
ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic Leukemia
|
Phase 4 |